par Nanda, Rita;Chow, Laura Q M LQ;Claire Dees, E.;Berger, Raanan;Gupta, Shilpa;Geva, Ravit;Pusztai, Lajos;Pathiraja, Kumudu;Aktan, Gursel;Cheng, Jonathan D;Karantza, Vassiliki;Buisseret, Laurence
Référence Journal of clinical oncology, 34, 21, page (2460-2467)
Publication Publié, 2016-07
Référence Journal of clinical oncology, 34, 21, page (2460-2467)
Publication Publié, 2016-07
Article révisé par les pairs
Résumé : | Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. |